普萘洛尔和聚桂醇分别治疗小儿血管瘤的临床效果比较

目的 探讨普萘洛尔和聚桂醇分别治疗婴幼儿浅表皮肤血管瘤的临床疗效及不良反应.方法 60例符合入组条件的浅表皮肤血管瘤患儿按随机数字表法分为普萘洛尔口服治疗组(32例)和聚桂醇局部注射治疗组(28例).普萘洛尔组观察时间为6个月～1年.聚桂醇组总注射次数不超过3次,治疗结束后采用Achauer标准方法进行临床疗效评价,并记录两组治疗时间及不良反应.结果 普萘洛尔组、聚桂醇组有效例数分别为26例(81.25％)、21例(75.00％),普萘洛尔组有效率偏高,但两组比较差异无统计学意义(P＞0.05);普萘洛尔组、聚桂醇组不良反应的发生分别为12例(37.50％)、18例(64.29％),普萘洛尔组不良反应更少,且两组之间差异有统计学意义(P＜0.001);普萘洛尔组、聚桂醇组治疗时间分别为(160.73±43.79)、(54.93±14.96)d,聚桂醇组治疗时间较普萘洛尔组短(P ＜0.001).结论 口服普萘洛尔和局部注射聚桂醇治疗能有效治疗小儿浅表皮肤血管瘤,且普萘洛尔口服治疗不良反应更少.

A comparative analysis of propranolol and lauromacrogol injection in treatment of infantile hemangiomas

Objective To observe the efficacy of oral propranolol and lauromacrogol injection for treatment of infant superficial skin hemangiomas.Methods Sixty cases of infantile hemangiomas were randomly assigned into oral propranolol treatment group (32 cases) and 1% lauromacrogol injection group (28 cases).Propranolol treatment time was 6 months to 1 year,while the total dose times of 1% lauromacrogol injection was no more than 3 times.We used Achauer standard methods for clinical effect assessment,and recorded the clinical efficacy and side effects of the two groups.Results The effective rates of propranolol group and lauromacrogol injection group were 81.25% (26 cases) and 75.00% (21 cases),respectively.The effective rate of propranolol group was higher,but there was no significant difference between two groups (P>0.05).The side effects rates of propranolol group and lauromacrogol injection group were 37.50% (12 cases) and 64.29% (18 cases),respectively.The side effects rate of propranolol group was lower,and there was significant difference between two groups (P<0.001).The courses of treatment of propranolol group and lauromacrogol injection group were (160.73±43.79) d and (54.93±14.96) d,respectively,and 1% lauromacrogol injection group had a shorter course of therapy (P<0.001).Conclusions Propranolol and 1% lauromacrogol injection can effectively treat infant superficial skin hemangioma,and oral administration of propranolol had fewer side effects.